The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Shares of US biotech Novavax were up 9% at $8.72 by midday on Tuesday, after it revealed it has entered into a license ...

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

This big pharma stock still faces significant challenges in the new year.

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Pfizer exits ViiV Healthcare with a $1.89bn payout, while GSK retains its majority stake amid the shareholder shake-up.

In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Pfizer’s stake in ViiV Healthcare will be taken over by Shiongi, another minority shareholder in the HIV medicines company.